Vaginal misoprostol prior to diagnostic hysteroscopy in patients of reproductive age: a randomized clinical trial.
OBJECTIVE
To assess pain during and after diagnostic hysteroscopy in patients of reproductive age according to use of vaginal misoprostol.


METHODS
A randomized, triple-masked, controlled clinical trial (Canadian Task Force classification I).


METHODS
Diagnostic center at Instituto Materno Infantil de Pernambuco-Brazil.


METHODS
A total of 45 women of reproductive age underwent diagnostic anesthesia-free hysteroscopy.


METHODS
In all, 400 mg of vaginal misoprostol or placebo was administered to randomized patients before diagnostic hysteroscopy.


RESULTS
The clinical trial was interrupted in patients receiving misoprostol because of significant vaginal bleeding precluding the procedure (p = .0006). No significant difference existed in pain scores between the groups. Vaginal bleeding was the main side effect occurring in 11 patients of the misoprostol group. No vaginal bleeding occurred in the placebo group (p = .00002).


CONCLUSIONS
In the doses used, vaginal misoprostol induced vaginal bleeding and precluded diagnostic hysteroscopy in patients of reproductive age that limits continuation of this line of research. Further studies are needed to reassess the use of the drug in patients of this age group.
Valente
Emanuelle Pessa
EP
Instituto Materno-Infantil Prof. Fernando Figueira, Recife, Brazil. emanuellevanlente01@hotmail.com
de Amorim
Melania Maria Ramos
MM
Costa
Aurélio Antônio Ribeiro
AA
de Miranda
Danielle Veríssimo
DV
D000282:Administration, Intravaginal; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D004106:Dilatation / Q000379:methods*; D005260:Female; D006801:Humans; D015907:Hysteroscopy; D016595:Misoprostol / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D010146:Pain / Q000517:prevention & control; D010147:Pain Measurement; D011300:Preoperative Care
D010120:Oxytocics; D016595:Misoprostol